Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

viteia pty ltd - irbesartan, quantity: 300 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; povidone; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

viteia pty ltd - irbesartan, quantity: 75 mg - tablet - excipient ingredients: croscarmellose sodium; lactose monohydrate; povidone; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; lactose monohydrate; hyprolose; titanium dioxide; croscarmellose sodium; colloidal anhydrous silica; macrogol 6000; purified talc; microcrystalline cellulose; iron oxide red; iron oxide yellow - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 150 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; titanium dioxide; magnesium stearate; hypromellose; calcium hydrogen phosphate; iron oxide yellow; povidone; iron oxide red; hyprolose - for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; hydrogenated castor oil; colloidal anhydrous silica; maize starch - irbesartan hct medis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; lactose monohydrate; iron oxide red; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; iron oxide yellow; macrogol 6000; hyprolose; magnesium stearate; colloidal anhydrous silica - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type b; polysorbate 80; mannitol; hypromellose; magnesium stearate; povidone; titanium dioxide; iron oxide red; macrogol 3350; carnauba wax; iron oxide black - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - irbesartan, quantity: 300 mg - tablet - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; povidone; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - irbesartan, quantity: 75 mg - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; microcrystalline cellulose; povidone; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; pregelatinised maize starch; povidone; colloidal anhydrous silica; croscarmellose sodium; poloxamer; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; iron oxide black - treatment of hypertension. treatment should not be initiated with this fixed dose combination.